Anlotinib for previously treated advanced or metastatic esophageal squamous cell carcinoma: A double ‐blind randomized phase 2 trial

ConclusionsThe use of anlotinib in previously treated, recurrent, or metastatic ESCC patients significantly improved PFS compared with placebo. Our findings suggest that antiangiogenesis might be an important therapeutic target in advanced ESCC.Clinical Trials RegistrationStudy of Anlotinib in Patients With Esophageal Squamous Cell Carcinoma (ALTER1102), NCT02649361.

Source: Cancer Medicine - February 15, 2021 Category: Cancer & Oncology Authors: Jing Huang, Juxiang Xiao, Wentao Fang, Ping Lu, Qingxia Fan, Yongqian Shu, Jifeng Feng, Shu Zhang, Yi Ba, Yang Zhao, Ying Liu, Chunmei Bai, Yuxian Bai, Yong Tang, Yan Song, Jie He Tags: ORIGINAL RESEARCH Source Type: research